Tobias Walbert
A5026869480- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiopharmaceutical Chemistry and Applications
- Palliative Care and End-of-Life Issues
- Cancer, Hypoxia, and Metabolism
- Epigenetics and DNA Methylation
- Meningioma and schwannoma management
- Cancer Research and Treatments
- ATP Synthase and ATPases Research
- Cancer Genomics and Diagnostics
- Pituitary Gland Disorders and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Childhood Cancer Survivors' Quality of Life
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Neuroblastoma Research and Treatments
- Cancer-related cognitive impairment studies
- Virus-based gene therapy research
- Pharmacological Effects and Toxicity Studies
- Cancer survivorship and care
- Histone Deacetylase Inhibitors Research
- Management of metastatic bone disease
Henry Ford Health System
2016-2025
Henry Ford Hospital
2015-2025
Wayne State University
2020-2025
Michigan State University
2023-2025
University of Rochester Medical Center
2024
Northwestern University
2024
Haukeland University Hospital
2024
Duke University Hospital
2024
Duke Medical Center
2024
University of Florida
2020
Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard newly diagnosed glioblastoma.After surgery chemoradiotherapy, patients were randomized (2:1) receive temozolomide plus DCVax-L (n = 232) or placebo 99). Following recurrence, all allowed DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); secondary...
Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.This phase 3, prospective, externally controlled nonrandomized trial compared overall (OS) in newly diagnosed (nGBM) recurrent (rGBM) treated DCVax-L plus SOC vs contemporaneous matched external...
Abstract Background Variability in standard-of-care classifications precludes accurate predictions of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection who would benefit from adjuvant radiotherapy to delay recurrence. We aimed develop an individualized prediction model risk combining clinical and molecular factors meningioma. Methods DNA methylation profiles clinically annotated samples across multiple institutions were used a methylome 5-year...
Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently administered courses of the prodrug FC (extended-release 5-fluorocytosine) into antimetabolite 5-fluorouracil. Forty-five subjects with recurrent or progressive high-grade glioma were treated. The end points this phase 1, open-label, ascending dose, multicenter trial included safety, efficacy, and molecular profiling;...
Treatment of the tumor and dural margin with surgery sometimes radiation are cornerstones therapy for meningioma. Molecular classifications have provided insights into biology disease; however, response to treatment remains heterogeneous. In this study, we used retrospective data on 2,824 meningiomas, including molecular 1,686 tumors 100 prospective from RTOG-0539 phase 2 trial define biomarkers response. Using propensity score matching, found that gross resection was associated longer...
Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine FC), results preclinically local production of 5-fluorouracil, depletion immune-suppressive myeloid cells, and subsequent induction antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months....
Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, an antibody-drug conjugate that preferentially binds cells EGFR amplification, internalized and releases potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, efficacy depatux-m monotherapy at recommended Phase 2 dose...
<h3>Importance</h3> New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma. <h3>Objective</h3> To compare overall survival for receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) flucytosine FC) vs standard care (SOC). <h3>Design, Setting, and Participants</h3> A randomized, open-label phase 2/3 trial (TOCA 5) in 58 centers US, Canada, Israel, South Korea, comparing posttumor treatment Toca 511 FC a defined single choice...
Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse no clear standard of care for recurrent disease (rGBM). Approximately 50% patients tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody-drug conjugate depatuxizumab mafodotin (depatux-m) binds cells EGFR amplification, is internalized, and releases microtubule toxin, killing the cell. Here we report efficacy, safety pharmacokinetics (PK) depatux-m + temozolomide (TMZ) in...
There is a critical need for objective and reliable biomarkers of outcome in meningiomas beyond WHO classification. Loss H3K27me3 has been reported as prognostically unfavorable alteration meningiomas. We sought to independently evaluate the reproducibility prognostic value loss by immunohistochemistry (IHC) multicenter study.IHC staining analyses whole slides from 181 across three centers was performed. Staining analyzed dichotomization into retained immunoreactivity, using 3-tiered scoring...
The detection of somatic mutations in cell-free DNA (cfDNA) from liquid biopsy has emerged as a noninvasive tool to monitor the follow-up cancer patients. However, significance cfDNA clinical utility remains uncertain patients with brain tumors, primarily because limited sensitivity detect real tumor-specific mutations. This unresolved challenge prevented accurate glioma approaches.Genome-wide methylation profiling tumor tissue and serum patients.Here, we developed approach profile status...
Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim the study was to determine safety clinical activity olutasidenib in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation.This open-label, multicenter, nonrandomized, phase Ib/II trial. Eligible (≥18 years) had histologically confirmed IDH1R132X-mutated glioma that relapsed or progressed on following standard therapy...
Abstract Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) tissue samples from 155 meningioma patients, compared other central nervous system tumor non-tumor entities. We discover markers unique use artificial...
Few studies have evaluated the health-related quality of life (HRQoL) patients with meningiomas. Here, we report largest prospective, longitudinal cross-sectional cohort study HRQoL in meningiomas to date, order identify possible actionable determinants global HRQoL.Adults who had undergone resection a grade I intracranial meningioma and were routine follow-up at single large tertiary center underwent assessment using QLQ-C30 questionnaire administered opportunistically visits. Averaged...
Abstract Background Ofranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study survival benefit for patients with recurrent glioblastoma (rGBM) who were primed VB-111 monotherapy was continued after progression concomitant bevacizumab. Methods This pivotal III randomized, controlled trial compared the efficacy and safety of upfront combination bevacizumab versus monotherapy. Patients randomized 1:1 to receive 1013 particles every 8 weeks 10 mg/kg 2...